As the global economy mends, the 2021 growth of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) will have significant change from previous year. According to our (LP Information) latest study, the global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market size will reach USD million in 2028, growing at a CAGR of % over the analysis period 2022-2028.
The United States Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market, reaching US$ million by the year 2028. As for the Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.
Global main Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) players cover Abbott, Amgen, Arven Pharmaceuticals, and Biocon, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Vials
Prefilled
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Myelosuppressive Chemotherapy
Leukemia Chemotherapy
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Abbott
Amgen
Arven Pharmaceuticals
Biocon
Cadila Pharmaceuticals
Dr.Reddy's Laboratories
Emcure Pharmaceuticals
Intas Pharmaceuticals
Kyowa Kirin
Novartis
Pfizer
Reliance Life Sciences
Harbin Pharmaceutical
North China Pharmaceutical
Jiuyuan Gene
Kexing Biopharm
Qilu Pharmaceutical
Quangang Pharmaceutical
Sunway Biotech
SL Pharmaceutical
Four Rings Bio-Pharmaceutical
Amoytop
Wuzhong Pharmaceutical